Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
Baxter
Harvard Business School
Boehringer Ingelheim

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

GOCOVRI Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Gocovri, and when can generic versions of Gocovri launch?

Gocovri is a drug marketed by Adamas Pharma and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in seven countries.

The generic ingredient in GOCOVRI is amantadine hydrochloride. There are seven drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amantadine hydrochloride profile page.

Summary for GOCOVRI
International Patents:23
US Patents:14
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 130
Patent Applications: 6,808
Formulation / Manufacturing:see details
Drug Prices: Drug price information for GOCOVRI
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for GOCOVRI
DailyMed Link:GOCOVRI at DailyMed
Drug patent expirations by year for GOCOVRI
Drug Prices for GOCOVRI

See drug prices for GOCOVRI

Recent Litigation for GOCOVRI

Identify potential future generic entrants

District Court Litigation
Case NameDate
ADAMAS PHARMA, LLC v. SANDOZ INC.2018-05-10
Osmotica Pharmaceutical US LLC v. Adamas Pharmaceuticals, Inc.2018-02-16

See all GOCOVRI litigation

Pharmacology for GOCOVRI
Drug ClassInfluenza A M2 Protein Inhibitor
Mechanism of ActionM2 Protein Inhibitors
Synonyms for GOCOVRI
(3R,5S,7s)-Adamantan-1-amine
(3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine
1-Adamantamine
1-Adamantamine(1-Aminoadamantane)
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantanamine, 96%
1-adamantaneamine
1-adamantanylamine
1-adamantyl amine
1-Adamantylamine
1-Adamantylamine, 97%
1-Amantadine
1-amino-adamantane
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
665-66-7 (hydrochloride)
744952-70-3
768-94-5
768A945
A838887
AB00053414_17
AB00053414_18
AB00053414-14
AB00053414-16
AB0014168
AB00514655
AB01275427-01
AC-25879
AC1L1CZI
AC1Q4UAF
AC1Q5396
ACT02873
Adamant-1-ylamine
Adamantamine
adamantan-1-amine
adamantan-1-ylamine
Adamantanamine
adamantane-1-amine
ADAMANTANE,1-AMINO
adamantaneamine
adamantanylamine
adamantyl amine
Adamantylamine
ADS-5102, EXP 105-1
AE-641/01634060
AJ-24589
AK-77141
AKOS000113994
AKOS000119324
AKOS007930692
AKOS015935124
AKOS022142354
ALBB-013871
Amant
Amantadina
Amantadina [INN-Spanish]
amantadine
Amantadine (INN)
Amantadine [INN:BAN]
Amantadine Base
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Aminoadamantane
AN-47537
ANW-43040
AS-14215
AX8000305
BBL004977
BBV-38789958
BC227869
BCP09869
BDBM50033369
BF4C9Z1J53
BIA4304
BIDD:GT0757
BP-13040
BPBio1_000368
BRD-K70330367-003-01-2
BRD-K70330367-003-03-8
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
C-02982
C06818
CA-1981
CAS-768-94-5
CC-03900
CCG-204100
CHEBI:2618
CHEMBL19601
CHEMBL660
CS-W008656
CTK3J2792
D07441
DB00915
DivK1c_000815
DKNWSYNQZKUICI-UHFFFAOYSA-N
DSSTox_CID_2117
DSSTox_GSID_22117
DSSTox_RID_76493
DTXSID8022117
EC 212-201-2
EINECS 212-201-2
EN300-33893
Endantadine
Exp-105-1 (Salt/Mix)
F0001-1962
FCH2250665
FT-0607338
Gen-Amantadine
GTPL4128
HMS1791O12
HMS1989O12
HMS3604O07
HSDB 3202
HTS001826
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
J-650234
K333
KB-87149
KBio1_000815
KBio2_000390
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
KS-00000X47
KSC492O9F
L000868
Lopac-A-1260
Lopac0_000004
LS-157049
M-4039
Mantadine
Mantadine (Salt/Mix)
MCULE-9686682307
MFCD00074732
MolPort-001-661-700
MolPort-001-791-102
MolPort-015-137-498
NCGC00015036-01
NCGC00015036-02
NCGC00015036-03
NCGC00015036-04
NCGC00015036-05
NCGC00015036-06
NCGC00015036-07
NCGC00015036-08
NCGC00015036-09
NCGC00015036-11
NCGC00015036-13
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC-341865
NSC341865
NSC83653
Oprea1_248648
OR14310
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
PubChem13903
PubChem8733
RP21518
RT-001031
SBB071506
SBI-0049993.P004
SC-06708
SCHEMBL15672299
SCHEMBL20409394
SCHEMBL2619248
SCHEMBL4098
SPBio_000002
SPBio_002273
Spectrum_000030
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
ST097860
ST2412621
STK298781
STR04703
Symadine
Symmetrel (Salt/Mix)
TCMDC-125869
TL8005280
Tox21_110068
Tox21_110068_1
TRA0073510
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
Tricyclo[3.3.1.13,7]decan-1-amine
Tricyclo[3.3.1.13,7]decane-1-amine
UNII-BF4C9Z1J53
W-104338
Wiregyt
WLN: L66 B6 A B- C 1B ITJ BZ
ZINC968256
ZX-AFC001530
ZX-AN012620
ZX-AT007596
Paragraph IV (Patent) Challenges for GOCOVRI
Tradename Dosage Ingredient NDA Submissiondate
GOCOVRI CAPSULE, EXTENDED RELEASE;ORAL amantadine hydrochloride 208944 2018-01-16

US Patents and Regulatory Information for GOCOVRI

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-001 Aug 24, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Adamas Pharma GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Dow
Merck
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
 NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews